Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility.
about
Prediction of metabolic drug interactions involving beta-adrenoceptor blocking drugsThe effect of propranolol on paracetamol metabolism in manEffect of atenolol and metoprolol on the anticoagulant activity of acenocoumarinInteraction between the beta-adrenoceptor blockers metoprolol and atenolol with amitriptyline and their effects on oxidative liver metabolism.The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin after a single doseFailure of 'therapeutic' doses of beta-adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaineOxidation phenotype and the metabolism and action of beta-blockers.Should every survivor of a heart attack be given a beta blocker? Part II. Evidence from a clinical pharmacological standpointThe impairment of lignocaine clearance by propranolol--major contribution from enzyme inhibitionLack of effect of atenolol and nadolol on the metabolism of theophylline.Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine.The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin.Inhibition of antipyrine metabolism by beta-adrenoceptor antagonistsPenbutolol and propranolol: a comparison of their effects on antipyrine clearance in manDiazepam/beta-adrenoceptor antagonist interactions.Polymorphic metabolism of beta-adrenoceptor antagonists.Comparison of beta-adrenoceptor antagonists as modulators of drug metabolism: effect of lipophilicity on microsomal phase I and II reactions.Lack of effect of atenolol on antipyrine clearance.
P2860
Q28365793-5F7EADCC-9530-400B-8D19-AB7F122118ACQ34398247-DBD97A70-4AA8-4E15-A30F-F85EB017E96FQ34620710-AAB172C5-2140-4907-93AE-689BAF463293Q34620733-46E0E33F-3274-44BF-9B6C-D40D6E1F3159Q34621307-BCFF5365-7928-407C-BCEA-D3E8A299DC64Q34622076-0BDC28C8-320E-4270-AE57-7FB94B4BD757Q39365323-1AF2FD03-124A-43BC-BD35-BBEB9B5F8AD6Q41128181-020A905B-3B2E-4CA7-86D2-8899BC66A666Q41339934-08DDAF78-CDCC-4D75-B467-F646C6B44E7CQ41853239-24BF9643-ACCA-472E-AEA4-0DC812B35D05Q42047474-92D390AE-A072-4BE2-8E46-2CA84A607737Q42129219-15936489-4335-45F6-8F24-5C22680A4F62Q42285279-0A02D634-E8B8-4D30-A11E-3AAAA909DED6Q42530741-A5E3E1C4-4019-40E8-ABA4-BDD6A3C0873EQ42532332-8C990550-5ADB-40FE-B0BB-8E62A5844E61Q42532367-547FE0AB-12C3-4D76-93C3-F32A5677A5FEQ42532378-64AFFC52-4596-489F-9579-FF3F8C5FF7E8Q43261488-D345B8E1-5DB3-46D3-A360-1761EE4323F9
P2860
Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility.
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年学术文章
@wuu
1981年学术文章
@zh
1981年学术文章
@zh-cn
1981年学术文章
@zh-hans
1981年学术文章
@zh-my
1981年学术文章
@zh-sg
1981年學術文章
@yue
1981年學術文章
@zh-hant
name
Inhibition of oxidative drug m ...... ted to their lipid solubility.
@en
Inhibition of oxidative drug m ...... ted to their lipid solubility.
@nl
type
label
Inhibition of oxidative drug m ...... ted to their lipid solubility.
@en
Inhibition of oxidative drug m ...... ted to their lipid solubility.
@nl
prefLabel
Inhibition of oxidative drug m ...... ted to their lipid solubility.
@en
Inhibition of oxidative drug m ...... ted to their lipid solubility.
@nl
P2093
P2860
P1476
Inhibition of oxidative drug m ...... ted to their lipid solubility.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1981.TB01240.X
P407
P577
1981-09-01T00:00:00Z